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This study aimed to develop niosomes of ellagic acid (EA), a potent antioxidant phyto-
chemical substance, for dermal delivery and to investigate the influence of chemical
penetration enhancers on the physicochemical properties of EA-loaded niosomes. The EA
niosomes were prepared by reverse phase evaporation method using Span 60, Tween 60
and cholesterol as vesicle forming agents and Solulan C24 as a steric stabilizer. Poly-
ethylene glycol 400 (PEG) was used as a solubilizer while dimethylsulfoxide (DMSO) or N-
methyl-2-pyrrolidone (NMP) was used as a skin penetration enhancer. It was found that the
mean particle sizes of EA-loaded niosomes were in the range of 312e402 nm with PI values
of lower than 0.4. The niosomes were determined to be spherical multilamellar vesicles as
observed by transmission electron microscope and optical microscopy. All niosomes were
stable after 4 months storage at 4 C. In vitro skin permeation through human epidermis
revealed that the skin enhancers affected the penetration of EA from the niosomes at 24 h.
The DMSO niosomes showed the highest EA amount in epidermis; whereas the NMP
niosomes had the highest EA amount in the acceptor medium. Concomitantly, the skin
distribution by confocal laser scanning microscopy showed the high fluorescence intensity
of the DMSO niosomes and NMP niosomes at a penetration depth of between 30e90 mm
(the epidermis layer) and 90e120 mm (the dermis layer) under the skin, respectively. From
the results, it can be concluded that the DMSO niosomes are suitable for epidermis delivery
of EA while the NMP niosomes can be used for dermis delivery of EA.
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a s i a n j o u rn a l o f p h a rm a c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 1 1 0e1 1 7 1111. Introduction the permeation enhancers to destabilize the lipid bilayers andThe self-assembly of non-ionic surfactants into vesicles rep-
resents an interesting opportunity to achieve vesicular
colloidal drug carriers, so-called niosomes, which resemble
liposomes in their architecture and can be used as an effective
alternative to liposomal drug carriers [1]. Niosomes have been
proposed for a number of potential therapeutic applications.
In particular, they have been intensively used as effective
dermal and transdermal drug delivery systems [2e5]. Ellagic
acid (EA) is a potent antioxidant phytochemical substance
which has skin-whitening property with photoprotective ef-
fect [6-7]. However, it is poorly soluble inwater (w9.7 mg/ml) [8]
and not soluble in many organic solvents, leading to diffi-
culties in the design of pharmaceutical formulations. In our
previous study [9], we demonstrated that the 2:1 Span 60 and
Tween 60 niosomes were able to encapsulate and deliver EA
through human epidermis and dermis.
One generalized approach to overcome the barrier prop-
erties of the skin for drugs and biomolecules is an incorpora-
tion of suitable vehicles or other chemical compounds into
transdermal delivery systems. Substances that promote the
penetration of topically applied drugs through stratum cor-
neum and epidermis are commonly referred to as skin
permeation enhancers, accelerants, adjuvants, or sorption
promoters [10]. Chemical skin permeation enhancers have
been generally used to promote the drug permeation through
the skin [11,12]. Dimethylsulfoxide (DMSO) is one of the
earliest and most widely studied penetration enhancers and
often used in many areas of pharmaceutical sciences as a
“universal solvent”. It has been postulated that DMSO de-
natures the intercellular structural protein of the stratum
corneum [13], or promote lipid fluidity by disruption of the
ordered structure of the lipid chains [14]. Although DMSO at
high concentration of >60% was reported to induce erythema
and wheals of the stratum corneum, it has been used as
nonirritant skin penetration enhancer at 10% in many skin
formulations [15]. N-methyl-2-pyrrolidone (NMP) is a polar
aprotic solvent and miscible with most common solvents
including water and alcohols. NMP can partition well into
human stratum corneum. Within the tissue, it may act by
altering the solvent nature of membrane and has been used
to generate “reservoirs” within skin membranes [16]. It was
also used as skin penetration enhancer in many topical for-
mulations at the concentration up to 40% without any skin
sensitization [17e19]. However, it has been reported that NMP
metabolite, 5-hydroxy-N-methyl pyrrolidone was observed in
urine after skin exposure with 5% solution of NMP [20]. To our
knowledge, there are no reports on use of NMP as a penetra-
tion enhancer in formulation of liposomes and niosomes.
Hence, it is of our interest to investigate the potential of DMSO
and NMP to enhance skin permeation of EA when added into
niosomal formulations. In this study, the EA-loaded niosomes
were prepared by using mixture of two non-ionic surfactants,
2:1 Span 60 and Tween 60, and cholesterol as the main com-
ponents of the vesicular bilayer. In addition, Solulan C24 and
two chemical penetration enhancers (10% v/v DMSO and 1% v/
v NMP) were used as membrane additives. The vesicular sys-
tems were characterized in order to evaluate the capability ofto improve dermal delivery of EA.2. Materials and methods
2.1. Materials
Sorbitan monostearate (Span 60) and polyethylene glycol
sorbitan monostearate (Tween 60) were obtained from Uni-
qema (Chicago, USA). Ellagic acid (EA) and polyethylene glycol
400 (PEG) were purchased from Fluka (West St. Paul, USA).
Cholesteryl poly-24-oxyethylene ether (Solulan C24) was
received as a gift sample from Amerchol (New Jersey, USA).
Cholesterol and N-methyl-2-pyrrolidone (NMP) were pur-
chased from Sigma-Aldrich (St. Louis, MO, USA). Dime-
thylsulfoxide (DMSO) was obtained from Amresco (Ohio,
USA). All other solvents were of HPLC grade and triple distilled
water was used.
2.2. Preparation of EA-loaded niosomes
The vesicles were prepared by reverse phase evaporation
(REV) method [21] using 1:1 mole ratio of surfactants and
cholesterol as vesicle forming agents. The surfactants (2:1
Span 60 and Tween 60), cholesterol, 5 mol% and Solulan C24
and were dissolved in diethyl ether (organic phase) with and
without addition of 10% v/v DMSOor 1% v/v NMP. To solubilize
EA, 15% v/v PEG was added into an aqueous phase containing
1 mol% EA. At 1.5:1 the organic phase: the aqueous phase, the
aqueous phasewas added to the lipidmixture andmixed until
a homogeneous w/o emulsion was obtained. The w/o emul-
sion was sonicated at 7 C for 10 min. Afterwards, diethyl
ether was slowly removed under reduced pressure using a
rotary evaporator (60 rpm) until niosomal suspension was
completely formed. The dispersion was evaporated about
15 min and then nitrogen gas was purged into dispersion for
substitution of diethyl ether. In order to obtain niosomes with
homogeneous size, REV vesicles were sonicated for 15 min
and submitted to extrusion process for 3 times by an extruder
device (Lipex, Northern Lipids, BC, Canada), equipped with a
400 nmpore size polyestermembrane (Cyclopore, Whatman,
NJ, USA). The maximum pressure was set at 800 psi as well as
the temperature was controlled at 45 C during the extrusion
process.
2.3. Characterization of niosomes
Niosomes were characterized by optical microscopy and
transmission electron microscopy (TEM) for vesicle formation
and morphology. Optical micrographs were obtained with a
Nikon TE-2000 inverted light microscope (magnification
900). For TEM, a drop of vesicle dispersion was applied to a
200 mesh formvar copper grid and was stained with a 1%
phosphotungstic acid. Then samples were observed under a
transmission electron microscope (Hitachi Model H-7000,
Tokyo, Japan).
Size and size distribution of niosomes were determined by
photon correlation spectroscopy (PCS) with a Malvern
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 1 1 0e1 1 7112Zetasizer ZS (Malvern Instruments, UK). The mean particle
size (z-ave) and polydispersity index (PI) values were obtained
by averaging of 10 measurements at an angle of 90 in 10 mm
diameter cells at 25 C. The real refractive index and the
imaginary refractive index were set at 1.456 and 0.01,
respectively.
2.4. Determination of entrapment efficiency
The percentage of EA-loaded niosomes (% E.E.) was deter-
mined by ultrafiltration using centrifugal filter tubes with a
molecular weight cut-off of 30 kDa which were centrifuged
(Optima Model LE-80K, Beckman, USA) at 10,000 rpm for
15min. Niosomal pellets were dissolved inmethanol and then
diluted 10 folds with methanol and 0.1% v/v phosphoric acid
in water (1:1 v/v). The concentrations of EA in EA-loaded
niosomes and ultrafiltrate (free drug) were analyzed using
HPLC method. Each formulation was performed in duplicates
and each replicate sample was diluted and analyzed for three
times. The percentage of EA entrapment efficiency was
calculated using the following equation:
% E:E: ¼ Amount of loaded EA in niosomes
Total amount of added EA
 100
2.5. HPLC analysis
EA concentrations were measured by HPLC (Agilent 1200
series, Waldbronn, Germany). The stationary phase
was Hypersil ODS C18 reversed-phase column (250 mm 
4.6 mm  5 mm) used in isocratic mode at ambient temper-
ature. The mobile phase was a mixture of 0.1% phosphoric
acid, methanol and acetronitrile (42:48:10, v/v). The UV
detection was performed at a wavelength of 254 nm, the flow
rate was 0.8 ml/min and the injection volume was 20 ml. Prior
to the analysis, the HPLC validation parameters including
precision, accuracy and linearity were determined according
to USP guideline [22]. Linearity was observed in concentration
range of 0.05e10 mg/ml with a correlation coefficient value of
0.9999. The valves of coefficients of variation for intraday and
interday were less than 2% and the percent recovery was
100.15%.
2.6. Stability of EA-loaded niosomes
The niosomal dispersions were stored at 4, 25 and 40 C. The%
remaining of EA in the niosomes was evaluated by HPLC
spectrophotometry over 4-month periods.
2.7. Skin permeation study
2.7.1. Skin preparation
Human skin samples were obtained by abdominoplasty sur-
geries from female patient ranging in age from 25 to 60 years
supported by Yanhee Hospital, Bangkok, Thailand. The study
was carried out with the approval of the Committee on
Human Rights Related to Human Experimentation, Mahidol
University, Bangkok, Thailand. The excess adipose layer was
sectioned off from the received tissues by dissecting with the
surgical scissors. Then, the skin composed of epidermis andunderlying dermis was further used for in vitro skin distribu-
tion study. For in vitro permeation study, the epidermis was
separated from the dermis using the heat separation tech-
nique. The skin was immersed into hot water controlled
temperature at 60 C for 1 min. Then, the epidermal layer was
carefully separated from the dermis using blunt forceps to
produce intact sheets ready for mounting on diffusion cells.
The obtained epidermis was wrapped with aluminium foil
and stored at 20 C until used. The stored epidermis was
allowed to thaw, cut into 4.5  4.5 cm2 pieces and hydrated by
placing in isotonic phosphate buffer in a refrigerator (at about
4 C) overnight before used.
2.7.2. In vitro permeation study
In vitro permeation studies through human epidermis were
investigated using Franz diffusion cells. The diffusion cells
were thermo-regulated with a water jacket at 37 C. The
epidermis was excised from human skins and mounted on
Franz diffusion cells. A mixture of isotonic phosphate buffer
pH 5.5 and isopropyl alcohol at the ratios of 90 and 10 (%, v/v)
was used as an acceptormedium to provide the sink condition
during the experiment and because of an appropriate solubi-
lity of EA in isopropyl alcohol. After 24 h, the amounts of EA in
acceptor fluids and in the epidermis were analyzed by HPLC
spectroscopy.
To determine EA in the epidermis, the epidermis was
removed and rinsed with water and isopropanol and subse-
quently dried with a cotton swab. This procedure was done in
triplicate. Briefly, the skins were cut into small pieces and
soaked in 1 ml of methanol for 12 h in a closed tube. Subse-
quently, it was subjected to an ultrasonic for three cycles of
15 min to avoid the raise in the temperature during extraction
process. To ensure sufficient extraction of EA from skin, the
residual extracted skin was performed in the samemanner as
mentioned above. It was found that no HPLC peak signal of EA
was detected (LOD ¼ 10 ng/ml) indicating a complete extrac-
tion at the first extraction.
2.8. Skin distribution study
To investigate the distribution of EA from niosomal formula-
tions after being applied on the human skin, confocal laser
scanning microscopy (CLSM) was performed. Fortunately, EA
molecule can be detected by fluorescence detector. Therefore,
EA distribution in the different skin layers was investigated
using CLSM (FluoView FV1000 with IX2 inverted microscope:
Multi-line Argon laser exciting wavelengths of 457 and
488 nm, and HeliumeNeon green laser exciting wavelength of
543 nm). The emission wavelengths were set at 488 and
547 nm. The images were recorded by setting the camera
integration time to 10ms. Sample speedwas 4.0 mm/pixel. The
objective lens was in the magnification of 20 (Olympus, mi-
croscope, Japan).
In this study, the mixture of phosphate buffer pH 5.5 and
isopropyl alcohol at the ratio of 90 and 10 (%, v/v) was used as
an acceptor medium. After applying EA-loaded niosomes and
EA solution on the skin surface, at 24 h, the skin was rinsed
with distilled water. Then, the treated skins were removed
from the Franz diffusion cells. The skin was sectioned into the
pieces of 1 cm2 size and evaluated for depth of EA penetration.
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optically scanned at different increments through the z-axis
of a CLS microscope. The skin slices were investigated under
both normal light and fluorescence microscopes. The images
from the two techniques were overlaid to obtain the infor-
mation of the EA distribution in the different skin layers.
2.9. Statistical analysis
Statistical analysis of difference in the physicochemical
properties among predetermined intervals in the some
formulation and between formulations was performed by
using paired-t test and one-way analysis of variance (one-way
ANOVA), respectively. The level of significance was taken at p
value of 0.05.
Fig. 2 e Percentage of EA remaining after 4 months of
storage at 4, 25, 40 C for EA-loaded niosomes containing
15% v/v PEG without chemical enhancers (E-PEG) and with
10% v/v DMSO (E-DPEG) or 1% v/v NMP (E-NPEG).
3. Results and discussion
3.1. Morphology, vesicle size and % entrapment
efficiency
Vesicle formation in the presence of the enhancers was
confirmed by optical microscopy and TEM. Fig. 1 (A1, A2)
shows the obtained niosomes were spherical shape and
multilamellar vesicles under optical microscope which theFig. 1 e Photomicrographs of EA-loaded niosomes containing 15
from; (A1, B1) optical microscope (magnification 9003) and (A2,mean vesicle sizes in submicron range. In addition, the similar
results were displayed by TEM images as shown in Fig. 1 (A2,
B2). In general, an addition of chemical penetration enhancers
(10% v/v DMSO or 1% v/v NMP) into the niosomal formulations
did not alter vesicle formation. The vesicles could normally% v/v PEG and (A1, A2) 10% v/v DMSO or (B1, B2) 1% v/v NMP
B2) transmission electron microscopy (TEM).
Table 1 e Mean vesicle size (z-ave), polydispersity index (PI) and % entrapment efficiency of EA-loaded niosomes.
Formulation Before extrusion After extrusion Entrapment
efficiencyd (%)
EA-free niosomes EA-loaded niosomes EA-loaded niosomes
z-ave (nm) PI z-ave (nm) PI z-ave (nm) PI
E-PEGa 408  5 0.387  0.021 427  4 0.425  0.011 390  3 0.360  0.016 25.63  1.04
E-DPEGb 511  3 0.273  0.006 515  17 0.424  0.041 402  4 0.235  0.014 31.04  2.01
E-NPEGc 396  4 0.423  0.023 560  28 0.504  0.066 312  2 0.226  0.037 38.73  1.58
a The 2:1 Span 60:Tween 60 niosomes contained 15% v/v PEG without skin enhancers.
b The 2:1 Span 60:Tween 60 niosomes contained 15% v/v PEG with 10% v/v DMSO.
c The 2:1 Span 60:Tween 60 niosomes contained 15% v/v PEG with 1% v/v NMP.
d The values are expressed as the mean  SD from at least three batches.
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white dispersion of niosomes without large dispersed parti-
cles or curd was obtained.
The vesicle sizes of all EA-free niosomes were in the range
of 396e511 nm, as seen in Table 1. After EAwas entrapped into
the niosomes, the vesicle size of the niosomes significantly
increased ( p > 0.05). In addition, after submitted to extrusion
process, the niosomes of small and homogeneous size were
obtained with the mean vesicle size of 312e402 nm and PI
values lower than 0.4 (Table 1). Interestingly, after extrusion
the vesicle sizes of the DMSO niosomes were larger than the
NMP niosomes which may be due to the fact that NMP could
havemore effect on increasing fluidity of vesicularmembrane
resulting in ease of size reductionwhen subjected to extrusion
process. The change of niosomes size is an important
parameter which can influence both vesicular properties such
as entrapment efficiency and stability, as well as skin-vesicle
interactions.
The % E.E. of all niosomes was in between 25.63% and
38.73% (Table 1). In particular, the addition of DMSO and NMP
increased % E.E of the niosomes. This may be resulted from
the high solubility of EA in the enhancers (6.15mg/ml in DMSO
and 55.42 mg/ml in NMP). The DMSO niosomes had the lower
entrapment efficiency than the NMP niosomes which may be
described as the lower solubility of EA in DMSO. The higher %
E.E. of NMP niosomes could be explained from the high solu-
bility of EA in both PEG and NMP, and PEG molecules can
localize between double vesicular layers whichmay also carry
associated NMP with them. In addition, it was reported that
NMP acts as penetration enhancer by fluidizing lipid domain
(alkyl chains) of the stratum corneum [23,24]. The presence of
NMP in the niosome bilayer could produce the same effect,
fluidizing lipid domain of vesicle membrane, leading to an
increased space in the bilayer for the EA incorporation.Fig. 3 e In vitro skin permeation study of EA solution, EA-
loaded niosomes containing 15% v/v PEG without chemical
enhancers (E-PEG) and with 10% v/v DMSO (E-DPEG) or 1%
v/v NMP (E-NPEG) after applying for 24 h (n [ 3).3.2. Stability of EA-loaded niosomes
The results of the stability study of EA entrapped in various
niosomes stored at 4, 25 and 40 C for 4 months are shown in
Fig. 2. At 4 C, the EA in all niosomes exhibited a good stability,
which the percentages of EA remaining were almost 100. At
higher temperature (25 C), the percentages of EA remaining
decreased to 40%e60%. Likewise, at 40 C, they dramatically
decreased to below 30%. A direct relationship between a
decrease in % E.E. and the storage time as increasing thetemperature indicated the high degree of leaching. The higher
EA leakage at higher temperature may be due to the higher
fluidity of lipid bilayers at high temperature [25].
It is well known that the gel to liquid phase transition
temperature of the vesicular bilayers played an important role
in niosome formation and stability which was influenced by
types of non-ionic surfactants, mole ratio of surfactant and
cholesterol [1]. The stability of niosomes would be improved
by increasing the phase transition temperature of the system
by changing surfactant type and the surfactant/lipid level.
3.3. In vitro permeation of EA-loaded niosomes
Fig. 3 shows the amount of EA in the epidermis and the
acceptor medium after applying EA-loaded niosomes or EA
solution for 24 h. The amount of EA in epidermis after
applying all niosomes was much higher than the EA solution.
In addition, the DMSO niosomes gave significantly higher
amount of EA in epidermis than the NMP niosomes.
Conversely, the NMP niosomes gave significantly higher
amount of EA in acceptor medium than the DMSO niosomes.
This indicated that the NMP niosomes could penetrate
through epidermis into dermis higher than the DMSO nio-
somes which may be resulted from the higher penetration
enhancement efficiency of NMP [26] which could promote
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chains [27]. Therefore, the DMSO niosomes gave an advantage
on the delivery to the epidermis layer, while the NMP nio-
somes were better for delivering EA to the dermis layer.
3.4. Skin distribution of EA-loaded niosomes
CLSM studies were conducted to evaluate the extent of
penetration and transdermal potential of the permeated sys-
tem as depicted an increase in both the depth of penetration
and in fluorescence intensity. The CLSM images were ob-
tained from overlaying the bright field images and fluores-
cence images of the same area. Each image was one of the z-
stack at 15 mm depth. Fig. 4 shows the fluorescence images of
the epidermis and dermis layers of human skin after being
treatedwith the EA-loaded niosomes. The CLSM images of the
DMSO niosomes (Fig. 4A) showed effectiveness in permeating
EA up to 120 mmwhich showed high fluorescence intensity at
the penetration depth between 30e90 mm (epidermis layer
depth) and lower fluorescence intensity at the depth up to
120 mm (underlying dermis depth). Thus, the DMSO niosomesFig. 4 e CLSM images revealing the penetration and distributio
DMSO niosomes and (B) the NMP niosomes for 24 h.had high ability to deliver EA to the viable epidermis layer
which small amount of EA penetrated into dermis layer.
Meanwhile, the penetration of the NMP niosomes to dermis
layer was better than the DMSO niosomes as revealed by the
higher fluorescence intensity of EA at the deeper skin layer
(90e120 mm depth), as shown in Fig. 4B. According to the ob-
tained results, it confirmed that the skin enhancers affected
the permeation of EA to the epidermis or dermis in accordance
with the results from in vitro permeation study.4. Conclusion
The niosomes of 2:1 Span 60 and Tween 60 using PEG as the
solubilizer could be formed in the presence of chemical en-
hancers (DMSO and NMP). The vesicle shape was spherical
multilamellar vesicles as assessed by optical microscopy and
TEM. The mean particle sizes were in range of 312e402 nm
and PI values were lower than 0.4. An addition of enhancers
increased the entrapment efficiency of the EA-loaded nio-
somes. The results of the skin distribution of EA-loadedn of EA within the human skin after treated with (A) the
Fig. 4 e (continued).
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in vitro permeation which showed that the DMSO niosomes
had the higher fluorescence intensity in the epidermis layer
whereas the NMP niosomes had the higher fluorescence in-
tensity in the dermis layer. Therefore, the chemical enhancers
influenced the permeation of EA from the EA-loaded niosomes
through the human skin.
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